Design and Validation of a UV Spectrophotometric Analytical Method for Apixaban Determination and Additive Interference Effect Examination

Year 2025, Volume: 9 Issue: 2, 238 - 246, 29.12.2025

Sena Enda Girgin , Mohammadmahdi Norouzi , Sevda Akay Sazaklioglu

https://doi.org/10.32571/ijct.1741060

Abstract

In this study, a simple, sensitive, and reliable UV-Vis spectrophotometric method was developed and validated for the quantification of the oral anticoagulant apixaban. During the method development phase, the wavelength at which apixaban exhibited maximum absorbance was determined, and absorbance values at different pH levels were examined to establish the optimum analysis conditions. The effect of the additives commonly found in pharmaceutical formulations containing apixaban on its absorbance was evaluated, and the additives caused statistically significant changes ranging from –3.93% to +7.32%. To determine the reliability and analytical performance of the method, stability, intra-day and inter-day reproducibility studies, the linear working range, precision, and accuracy of the method were evaluated. In addition, the recovery of apixaban from the commercial preparation Eliquis® tablets was studied to demonstrate the applicability of the developed method on pharmaceutical preparations. The recovery results indicated that the method provides a reliable alternative for quantifying apixaban in pharmaceutical dosage forms. The results obtained showed that the developed UV-Vis spectrophotometric method can be used effectively in routine quality control analyses and formulation studies of apixaban. The simplicity, economy, and rapidity of the method enable its wide-ranging use.

Keywords

Apixaban , UV-Vis spectroscopy , Pharmaceutical additives , Analytical method development

Project Number

1919B012427508

Thanks

The authors would like to thank Deva İlaç for kindly providing the active pharmaceutical ingredient used in this study. The study was supported by the 2209-A TÜBİTAK (Scientific and Technological Research Council of Turkey) Student Project (1919B012427508), and we would like to express our sincere gratitude to TÜBİTAK for their support.

References

• Ahsan, Z. & Bhaskar, A. (2025). Progress of Nanomedicine-Integrated Treatments for Pulmonary Embolism: A Review, Challenges, and Future Possibilities. Undergraduate Research in Natural and Clinical Science and Technology Journal 9(1) 1-15. https://doi.org/10.26685/urncst.694 Akbel, E., Bulduk, I. & Gökçe, S. (2023). A green HPLC method for the determination of apixaban in pharmaceutical products: Development and validation. Reviews in Analytical Chemistry, 42(1) 20230058-20230070. https://doi.org/10.1515/revac-2023-0058
• Aronson, J. K. & Hardman, M. (1992). ABC of Monitoring Drug Therapy Measuring Plasma Drug Concentrations. BMJ, 305(6861), 1078-80. https://doi.org/10.1136/bmj.305.6861.1078
• B. Mahendra, K. Harika Sundari & T. Vimalakkannan. (2019). Method developed for the determination of apixaban by using U.V. spectrophotometric. International Journal of Research In Pharmaceutical Chemistry and Analysis, 1(3), 83–87. https://doi.org/10.33974/ijrpca.v1i3.115
• Changizi Kecheklou, A., Afshar Mogaddam, M. R., Sorouraddin, S. M., Farajzadeh, M. A. & Fathi, A. A. (2024). Thin film microextraction of apixaban from plasma based on the covalent organic framework coated on a mesh prior to liquid chromatography-tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 1247, 124302-124309. https://doi.org/10.1016/j.jchromb.2024.124302
• Chernonosov, A., Aksenova, L. & Koval, V. (2021). The development of a liquid chromatography high‐resolution mass spectrometric method for apixaban quantification in dried plasma spots in parallel reaction monitoring mode. Processes, 9(3), 1–12. https://doi.org/10.3390/pr9030450
• Damle, M. C., Waghmare, S. S. & SINHA, P. (2019). Development and Validation of Stability Indicating HPTLC Method For Determination of Apixaban As Bulk Drug. International Journal of Pharmacy and Pharmaceutical Sciences, 11, 37–42. https://doi.org/10.22159/ijpps.2019v11i5.28071
• Douxfils, J., Ageno, W., Samama, C. M., Lessire, S., ten Cate, H., Verhamme, P., Dogné, J. M. & Mullier, F. (2018). Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians. In Journal of Thrombosis and Haemostasis, 16, 209–219. https://doi.org/10.1111/jth.13912
• Dudhe, P.B., Shelke P. S., & Chavare P.D. (2017). Determination of Apixaban from Bulk and Tablet Dosage Form by Area Under Curve and First Order Derivative Spectrophotometric Methods. International Journal of ChemTech Research, 10, 703-711.
• El-Bagary, R. I., Elkady, E. F., Farid, N. A. & Youssef, N. F. (2017). Validated spectrofluorimetric methods for the determination of apixaban and tirofiban hydrochloride in pharmaceutical formulations. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 174, 326–330.https://doi.org/10.1016/j.saa.2016.11.048
• Ellwanger, J. B., Wingert, N. R., Volpato, N. M., Garcia, C. V., Schapoval, E. E. S. & Steppe, M. (2020). Analytical Quality by Design Approach for a Stability-Indicating Method to Determine Apixaban and Its Related Impurities. Chromatographia, 83(1), 65–75. https://doi.org/10.1007/s10337-019-03815-9
• Hao, K., Meng, R., Bu, X., Liu, Z., Yan, H., Zhang, Y. & Guo, N. (2020). Antibacterial effect of caprylic acid and potassium sorbate in combination against listeria monocytogenes ATCC 7644. Journal of Food Protection, 83(6), 920–927. https://doi.org/10.4315/0362-028X.JFP-19-458
• Haque, M. A., Bakshi, V., Boggula, N. & Dandamudi, S. P. (2019). Method Development And Validations of Apixaban in Bulk and Its Formulations By UV-Spectroscopy (Area Under Curve). International Journal of Pharmaceutical Sciences and Research, 10(3), 18-22. https://doi.org/10.13040/IJPSR.0975-8232.10(3).1387-91
• Hebbink, G. A., Jaspers, M., Peters, H. J. W. & Dickhoff, B. H. J. (2022). Recent developments in lactose blend formulations for carrier-based dry powder inhalation. In Advanced Drug Delivery Reviews, 189, 114527-114550. https://doi.org/10.1016/j.addr.2022.114527
• Jain, H. K. & Nikam, V. K. (2017). Formulation Development and Stability Indicating HPLC Assay of Tablets of Apixaban. International Journal of Pharmacy and Pharmaceutical Sciences, 9(10), 24-32. https://doi.org/10.22159/ijpps.2017v9i10.20343
• Jhang, R. S., Lin, S. Y., Peng, Y. F., Chao, H. C., Tsai, I. L., Lin, Y. T., Liao, H. W., Tang, S. C., Kuo, C. H. & Jeng, J. S. (2020). Using the PCI-IS Method to Simultaneously Estimate Blood Volume and Quantify Nonvitamin K Antagonist Oral Anticoagulant Concentrations in Dried Blood Spots. Analytical Chemistry, 92(3), 2511–2518. https://doi.org/10.1021/acs.analchem.9b04063
• Komen, J., Forslund, T., Hjemdahl, P., Andersen, M. & Wettermark, B. (2017). Effects of policy interventions on the introduction of novel oral anticoagulants in Stockholm: an interrupted time series analysis. British Journal of Clinical Pharmacology, 83(3), 642–652. https://doi.org/10.1111/bcp.13150
• Lindahl, S., Dyrkorn, R., Spigset, O. & Hegstad, S. (2018). Quantification of Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in Human Serum by UHPLC-MS/MS-Method Development, Validation, and Application. Therapeutic Drug Monitoring, 40(3), 369-376. https://doi.org/10.1097/ftd.0000000000000509
• Lip, G. Y. H., Benamouzig, R., Martin, A. C., Pesce, G., Gusto, G., Quignot, N., Khachatryan, A., Dai, F., Sedjelmaci, F., Chaves, J., Subash, R. & Mokgokong, R. (2024). Comparative safety and effectiveness of oral anticoagulants in patients with non-valvular atrial fibrillation and high risk of gastrointestinal bleeding: A nationwide French cohort study. PLoS ONE, 19, 1-26. https://doi.org/10.1371/journal.pone.0310322
• Mandernach, M. W., Beyth, R. J. & Rajasekhar, A. (2015). Apixaban for the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism: An evidence-based review. In Therapeutics and Clinical Risk Management, 11, 1273–1282. https://doi.org/10.2147/TCRM.S68010
• Mandru, A., Mane, J. & Mandapati, R. (2023). A Review on UV-visible spectroscopy. 1(2), 091–096. https://doi.org/10.5281/zenodo.10232708
• Manjunath, K. M., Yemmi, R., Swamy, B. E. K., Eldesoky, G. E. & Govindasamy, M. (2025). Electrochemical sensor based on ZnO@MWCNT/ glassy carbon electrode for the detection of warfarin (blood anticoagulant). Surfaces and Interfaces, 67, 106602-106614. https://doi.org/10.1016/j.surfin.2025.106602
• Martin, K. & Moll, S. (2016). Direct oral anticoagulant drug level testing in clinical practice: A single institution experience. Thrombosis Research, 143, 40–44. https://doi.org/10.1016/j.thromres.2016.04.019
• Mavri, A., Vene, N., Božič-Mijovski, M., Miklič, M., Söderblom, L., Pohanka, A., Malmström, R. E. & Antovic, J. (2021). Apixaban concentration variability and relation to clinical outcomes in real-life patients with atrial fibrillation. Scientific Reports, 11(1). https://doi.org/10.1038/s41598-021-93372-9
• Nagavalli, D. & Nanthagopal, P. (2023). Pharmaceutical Applications for MANNITOL: An Overview. International Journal of Pharmaceutical Sciences and Medicine, 8(6), 103–138. https://doi.org/10.47760/ijpsm.2023.v08i06.008
• Picollo, M., Aceto, M. & Vitorino, T. (2019). UV-Vis spectroscopy. Physical Sciences Reviews, 4(4) 20180008- 20180021. https://doi.org/10.1515/psr-2018-0008
• Prabhune, S. S., Jaguste, R. S., Kondalkar, P. L. & Pradhan, N. S. (2014). Stability-indicating high-performance liquid chromatographic determination of apixaban in the presence of degradation products. Scientia Pharmaceutica, 82(4), 777–785. https://doi.org/10.3797/scipharm.1403-25
• Reddy, P., & Rani, G.T. (2017). Development and Validation of UV Spectrophotometric Method for the Determination of Apixaban in Bulk and Pharmaceutical Dosage Forms. Indo American Journal of Pharmaceutical Sciences, 4(08), 2425-2429. http://doi.org/10.5281/zenodo.846373
• Risman, R. A., Shroff, M., Goswami, J. & Tutwiler, V. (2024). Dependence of clot structure and fibrinolysis on apixaban and clotting activator. Research and Practice in Thrombosis and Haemostasis, 8(8), 102614- 102625. https://doi.org/10.1016/j.rpth.2024.102614
• Rizk, M., Sultan, M. A., Taha, E. A., Attia, A. K. & Abdallah, Y. M. (2017). Sensitive validated voltammetric determination of apixaban using a multi-walled carbon nanotube-modified carbon paste electrode application to a drug product and biological sample. Analytical Methods, 9(17), 2523–2534. https://doi.org/10.1039/c7ay00244k
• Rocha, M. O., Mohr, A., Kolling, L., da Silva, M. M., da Silva, J. A. & Steppe, M. (2024). Eco-Friendly Capillary Electrophoresis Method for the Quantification of Apixaban in Oral Dosage Form. Separations, 11(12), 346-358. https://doi.org/10.3390/separations11120346
• Salakolusu, S., Sharma, G. V. R., Katari, N. K., Puppala, U., Kaliyapermal, M., Vijay, R., Doddipalla, R. & Geereddi, M. K. R. (2022). Identification, isolation, and structural characterization of novel forced degradation products of apixaban using advanced analytical techniques. Journal of Separation Science, 45(21), 3942–3954. https://doi.org/10.1002/jssc.202200466
• Sharma, D., R. Chauhan, V. & B. Vyas, K. (2019). Spectrophotometric Determination of Apixaban in Bulk Drug and Oral Dosage Formulation. International Journal of Scientific Research in Science and Technology, 377–385. https://doi.org/10.32628/ijsrst207263
• Tantawy, M. A., El-Ragehy, N. A., Hassan, N. Y. & Abdelkawy, M. (2016). Stability-indicating spectrophotometric methods for determination of the anticoagulant drug apixaban in the presence of its hydrolytic degradation product. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 159, 13–20. https://doi.org/10.1016/j.saa.2016.01.029
• Zhu, J., Alexander, G. C., Nazarian, S., Segal, J. B. & Wu, A. W. (2018). Trends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation, 2010–2017. Pharmacotherapy, 38(9), 907–920. https://doi.org/10.1002/phar.2158